G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey and the executive team will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The virtual event is scheduled for September 12, 2022, at 7:00 AM ET. A live webcast and replay will be available on the company's Events & Presentations page.

G1 Therapeutics focuses on developing therapies for cancer, notably its first product, COSELA® (trilaciclib), and is advancing a tumor-agnostic development plan targeting various solid tumors.

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference. The fireside chat with G1 will be available at 7:00AM ET on September 12, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo and COSELA^® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

What is the date and time of G1 Therapeutics' participation in the investment conference?

G1 Therapeutics will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM ET.

How can I access the webcast of G1 Therapeutics' event?

The webcast of G1 Therapeutics' event will be available on their Events & Presentations page after the live session.

What is the main focus of G1 Therapeutics as a company?

G1 Therapeutics focuses on developing and commercializing therapies for cancer, including their first product, COSELA® (trilaciclib).

What cancers is G1 Therapeutics targeting with COSELA?

G1 Therapeutics is evaluating COSELA in various solid tumors, including colorectal, breast, lung, and bladder cancers.

Who is presenting at the H.C. Wainwright conference for G1 Therapeutics?

Jack Bailey, the CEO of G1 Therapeutics, will be presenting at the H.C. Wainwright conference.